Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment

Md Kamrul Hasan

doi:doi:10.11648/j.bs.20170302.12

| Peer-Reviewed

Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment

Md Kamrul Hasan

Published in Biomedical Sciences (Volume 3, Issue 2)

Received: 25 November 2016 Accepted: 13 February 2017 Published: 26 April 2017

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Diffuse large B-cell lymphomas (DLBCLs) are the most common and aggressive type of all the lymphomas. B cell lymphoma 6 (BCL6) oncogene is highly expressed in DLBCLs and one of the major reasons of treatment failure. Recent findings suggest that specific BCL6 inhibitor (FX1) disrupted formation of the BCL6 repression complex, reactivated BCL6 target genes, that in-turn suppressed growth of DLBCLs cells, primary human DLBCLs specimens, as well as induced regression of established tumors in mice derived from DLBCLs cells.

Published in	Biomedical Sciences (Volume 3, Issue 2)
DOI	10.11648/j.bs.20170302.12
Page(s)	55-57
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2017. Published by Science Publishing Group

Keywords

Diffuse Large B-Cell Lymphomas (DLBCLs), BCL6, FX1

References

[1]	Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 2015 Jan 1; 125(1): 22-32.
[2]	Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England journal of medicine 2002 Jan 24; 346(4): 235-242.
[3]	Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2006 Jul 1; 24(19): 3121-3127.
[4]	Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. The Lancet Oncology 2011 Oct; 12(11): 1013-1022.
[5]	Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2005 Aug 1; 23(22): 5027-5033.
[6]	Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000 Feb 3; 403(6769): 503-511.
[7]	Lenz G, Staudt LM. Aggressive lymphomas. The New England journal of medicine 2010 Apr 15; 362(15): 1417-1429.
[8]	Huynh KD, Bardwell VJ. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene 1998 Nov 12; 17(19): 2473-2484.
[9]	Huynh KD, Fischle W, Verdin E, Bardwell VJ. BCoR, a novel corepressor involved in BCL-6 repression. Genes & development 2000 Jul 15; 14(14): 1810-1823.
[10]	Ahmad KF, Melnick A, Lax S, Bouchard D, Liu J, Kiang CL, et al. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Molecular cell 2003 Dec; 12(6): 1551-1564.
[11]	Ghetu AF, Corcoran CM, Cerchietti L, Bardwell VJ, Melnick A, Prive GG. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer. Molecular cell 2008 Feb 15; 29(3): 384-391.
[12]	Huang C, Hatzi K, Melnick A. Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. Nature immunology 2013 Apr; 14(4): 380-388.
[13]	Iqbal J, Greiner TC, Patel K, Dave BJ, Smith L, Ji J, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 2007 Nov; 21(11): 2332-2343.
[14]	Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005 Nov 1; 106(9): 3183-3190.
[15]	Green MR, Vicente-Duenas C, Romero-Camarero I, Long Liu C, Dai B, Gonzalez-Herrero I, et al. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nature communications 2014; 5: 3904.
[16]	Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, et al. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. The Journal of clinical investigation 2016 Sep 1; 126(9): 3351-3362.
[17]	Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer cell 2010 Apr 13; 17(4): 400-411.

Cite This Article

Plain Text BibTeX RIS

APA Style

Md Kamrul Hasan. (2017). Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment. Biomedical Sciences, 3(2), 55-57. https://doi.org/10.11648/j.bs.20170302.12

Copy | Download

ACS Style

Md Kamrul Hasan. Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment. Biomed. Sci. 2017, 3(2), 55-57. doi: 10.11648/j.bs.20170302.12

Copy | Download

AMA Style

Md Kamrul Hasan. Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment. Biomed Sci. 2017;3(2):55-57. doi: 10.11648/j.bs.20170302.12

Copy | Download

@article{10.11648/j.bs.20170302.12,
  author = {Md Kamrul Hasan},
  title = {Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment},
  journal = {Biomedical Sciences},
  volume = {3},
  number = {2},
  pages = {55-57},
  doi = {10.11648/j.bs.20170302.12},
  url = {https://doi.org/10.11648/j.bs.20170302.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bs.20170302.12},
  abstract = {Diffuse large B-cell lymphomas (DLBCLs) are the most common and aggressive type of all the lymphomas. B cell lymphoma 6 (BCL6) oncogene is highly expressed in DLBCLs and one of the major reasons of treatment failure. Recent findings suggest that specific BCL6 inhibitor (FX1) disrupted formation of the BCL6 repression complex, reactivated BCL6 target genes, that in-turn suppressed growth of DLBCLs cells, primary human DLBCLs specimens, as well as induced regression of established tumors in mice derived from DLBCLs cells.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment
AU  - Md Kamrul Hasan
Y1  - 2017/04/26
PY  - 2017
N1  - https://doi.org/10.11648/j.bs.20170302.12
DO  - 10.11648/j.bs.20170302.12
T2  - Biomedical Sciences
JF  - Biomedical Sciences
JO  - Biomedical Sciences
SP  - 55
EP  - 57
PB  - Science Publishing Group
SN  - 2575-3932
UR  - https://doi.org/10.11648/j.bs.20170302.12
AB  - Diffuse large B-cell lymphomas (DLBCLs) are the most common and aggressive type of all the lymphomas. B cell lymphoma 6 (BCL6) oncogene is highly expressed in DLBCLs and one of the major reasons of treatment failure. Recent findings suggest that specific BCL6 inhibitor (FX1) disrupted formation of the BCL6 repression complex, reactivated BCL6 target genes, that in-turn suppressed growth of DLBCLs cells, primary human DLBCLs specimens, as well as induced regression of established tumors in mice derived from DLBCLs cells.
VL  - 3
IS  - 2
ER  -

Copy | Download

Author Information

Md Kamrul Hasan

Moores Cancer Center, University of California San Diego, La Jolla, USA

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Md Kamrul Hasan. (2017). Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment. Biomedical Sciences, 3(2), 55-57. https://doi.org/10.11648/j.bs.20170302.12

Copy | Download

ACS Style

Md Kamrul Hasan. Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment. Biomed. Sci. 2017, 3(2), 55-57. doi: 10.11648/j.bs.20170302.12

Copy | Download

AMA Style

Md Kamrul Hasan. Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment. Biomed Sci. 2017;3(2):55-57. doi: 10.11648/j.bs.20170302.12

Copy | Download

@article{10.11648/j.bs.20170302.12,
  author = {Md Kamrul Hasan},
  title = {Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment},
  journal = {Biomedical Sciences},
  volume = {3},
  number = {2},
  pages = {55-57},
  doi = {10.11648/j.bs.20170302.12},
  url = {https://doi.org/10.11648/j.bs.20170302.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bs.20170302.12},
  abstract = {Diffuse large B-cell lymphomas (DLBCLs) are the most common and aggressive type of all the lymphomas. B cell lymphoma 6 (BCL6) oncogene is highly expressed in DLBCLs and one of the major reasons of treatment failure. Recent findings suggest that specific BCL6 inhibitor (FX1) disrupted formation of the BCL6 repression complex, reactivated BCL6 target genes, that in-turn suppressed growth of DLBCLs cells, primary human DLBCLs specimens, as well as induced regression of established tumors in mice derived from DLBCLs cells.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment
AU  - Md Kamrul Hasan
Y1  - 2017/04/26
PY  - 2017
N1  - https://doi.org/10.11648/j.bs.20170302.12
DO  - 10.11648/j.bs.20170302.12
T2  - Biomedical Sciences
JF  - Biomedical Sciences
JO  - Biomedical Sciences
SP  - 55
EP  - 57
PB  - Science Publishing Group
SN  - 2575-3932
UR  - https://doi.org/10.11648/j.bs.20170302.12
AB  - Diffuse large B-cell lymphomas (DLBCLs) are the most common and aggressive type of all the lymphomas. B cell lymphoma 6 (BCL6) oncogene is highly expressed in DLBCLs and one of the major reasons of treatment failure. Recent findings suggest that specific BCL6 inhibitor (FX1) disrupted formation of the BCL6 repression complex, reactivated BCL6 target genes, that in-turn suppressed growth of DLBCLs cells, primary human DLBCLs specimens, as well as induced regression of established tumors in mice derived from DLBCLs cells.
VL  - 3
IS  - 2
ER  -

Copy | Download